A Phase III Study to Assess the Efficacy and Safety of Almonertinib Versus Platinum-based Chemotherapy as First-line Therapy in Patients With Locally Advanced or Metastatic NSCLC Harbouring Uncommon EGFR Mutation
Clinical trial NCT04951648 · UNKNOWN
Trial details
- NCT number
- NCT04951648
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
- Status
- UNKNOWN
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2021-07-15
- Primary completion
- 2023-10-04
- Enrollment
- 220
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.